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A B S T R A C T
Background: Electrocardiogram (ECG) abnormalities increase the likelihood of heart failure (HF) but 
have low specificity and their occurrence is multifactorial. 
Aim: This study aimed to investigate the prevalence and association of major ECG abnormalities with 
clinical characteristics and outcomes in a large cohort of real-life HF patients enrolled in HF Registries 
(Pilot and Long-Term) of the European Society of Cardiology.
Methods: Standard 12-lead ECG containing at least one of the following simple parameters was con-
sidered a major abnormality: abnormal rhythm; >100 bpm; QRS ≥120 ms; QTc ≥450 ms; pathological 
Q-wave; left ventricle hypertrophy; left bundle branch block. A Cox proportional hazards regression 
model was used to identify predictors of the primary (all-cause death) and secondary (all-cause death 
or hospitalization for worsening HF) endpoints. 
Results: Patients with abnormal ECG (1222/1460; 83.7%) were older, more frequently were male and had 
HF with reduced ejection fraction, valvular heart disease, comorbidities, higher New York Heart Association 
class, or higher concentrations of natriuretic peptides as compared to those with normal ECG. In a one-year 
follow-up, the primary and secondary endpoints occurred more frequently in patients with abnormal 
ECG compared to normal ECG (13.8% vs 8.4%; P = 0.021 and 33.0% vs 24.7%; P = 0.016; respectively). 
Abnormal rhythm, tachycardia, QRS ≥120 ms, and QTc ≥450 ms were significant in univariable (both 
endpoints) analyses but only tachycardia remained an independent predictor of the primary endpoint. 
Conclusions: HF patients with major ECG abnormalities were characterized by worse clinical status and 
one-year outcomes. Only tachycardia was an independent predictor of all-cause death.
Key words: tachycardia, electrocardiogram, QRS duration, left bundle branch block, heart rhythm 




1st Department of 
Cardiology, Medical 
University of Warsaw,
Banacha 1a, 02–097 
Warszawa, Poland,




Copyright by the Author(s), 
2021
Kardiol Pol. 2021; 









According to the heart failure (HF) guidelines of the Eu-
ropean Society of Cardiology (ESC), an electrocardiogram 
(ECG) is the basic examination that should be performed 
routinely in patients with suspected or known HF [1]. ECG 
abnormalities increase the likelihood of HF (89% sensitivity) 
but have low specificity [1]. The presence of ECG abnormal-
ities, especially in patients with HF, may depend on many 
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factors (e.g. ischemia, HF etiology, electrolyte disturbances, 
pharmacotherapy) and is often observed. ECG abnormal-
ities may be helpful in determining the HF etiology and 
making therapeutic decisions (e.g. anticoagulation in atrial 
fibrillation, pacing in bradycardia, cardiac resynchroniza-
tion therapy [CRT] when QRS complex is prolonged). Sev-
eral studies have also demonstrated that QRS duration or 
left bundle branch block (LBBB) can predict the risk of death 
in patients with chronic and decompensated HF [2–5]. Pro-
longed QTc (especially if genetically conditioned) may be 
associated with an increased risk of malignant ventricular 
arrhythmias, and ,in selected clinical situations, may be an 
indication for implantation of a cardioverter-defibrillator 
(ICD) [6]. The importance of ECG in clinical practice is 
undeniable, but particularly in the chronic setting of the 
disease, the results of this study are often overlooked. There 
is also insufficient data on the prevalence and role in risk 
stratification of major ECG abnormalities depending on the 
type of HF — HF with reduced (HFrEF), mid-range (HFmrEF) 
or preserved (HFpEF) ejection fraction. 
The aim of the study was to analyze the prevalence and 
association of easily measured major ECG abnormalities 
with clinical characteristics and outcomes in a large cohort 
of real-life HF patients enrolled in HF Registries (Pilot and 
Long-Term) of the ESC.
METHODS
Study design
The analysis is based on data from two HF Registries (the 
ESC-HF Pilot and the ESC-HF Long-Term) of the ESC. These 
registries were multicenter, prospective, observational 
surveys conducted in 136 (including 29 centers from 
Poland) and 211 European cardiology centers (including 
35 centers from Poland), respectively. A detailed study de-
sign was previously published [7, 8]. In short, the registries 
enrolled participants in outpatient and inpatient setting 
with chronic, worsening, or new-onset HF meeting diag-
nostic criteria for HF aged ≥18 years. There were no other 
specific exclusion criteria. The study protocol was approved 
by local ethics committees. All participating patients were 
provided with detailed information and signed written 
consent. The electronic Case Report Form contained data 
on past medical history, clinical characteristics, test results, 
HF management, and one-year follow-up. 
The current analysis concerns 2019 Polish patients. Full 
data on ECG recordings were available for 1611 patients, 
1460 patients had available data on the primary endpoint 
and were included in the final analysis. The prevalence 
of the major ECG changes was analyzed on a standard 
resting 12-lead ECG. ECG containing at least one of the 
following parameters was considered a major abnormality: 
abnormal rhythm; tachycardia (>100 bpm); duration of 
QRS complex ≥120 ms; QTc interval ≥450 ms (Bazett cor-
rection); pathological Q-wave; left ventricle hypertrophy; 
LBBB. Patients were divided into two groups according to 
the presence of ECG abnormalities and compared with 
regard to baseline clinical characteristics, type of HF (HFrEF, 
HFmrEF, and HFpEF), and one-year outcomes. The type of 
HF was defined by the authors based on baseline LVEF 
measurement. The primary endpoint was all-cause death 
at one year. The secondary endpoint was a composite of 
all-cause death and hospitalization for HF worsening at one 
year (follow-up available for 1326 participants). The New 
York Heart Association (NYHA) functional class with regard 
to the presence of ECG changes at baseline and 12-month 
was also evaluated. Data regarding participants’ status 
were collected via telephone follow-up from patients or 
their close relatives. If the contact was not possible, then 
the primary endpoint was ascertained from the data of the 
Polish National Health Fund.
Additionally, we sought to determine whether major 
ECG abnormalities were independent predictors of the 
primary and secondary endpoints in the study cohort.
Statistical analysis
The results were presented as median and quartiles for con-
tinuous variables and as frequencies and percentages for 
ordinal variables. Fisher’s exact test was used for compari-
son of categorical variables and a Mann-Whitney U test for 
continuous and ordinal variables. Cox proportional hazards 
regression models were used to identify predictors of the 
primary and secondary endpoints. All variables found to 
be statistically significant in univariable analyses (p <0.05) 
were included in multivariable analyses. Kaplan-Meier sur-
vival curves were plotted for both study endpoints. A P-val-
ue below 0.05 was considered significant for all tests. All 
tests were two-tailed. Statistical analyses were performed 
using SPSS software, version 22 (IBM SPSS Statistics 22, 
New York, NY, USA).
W H A T ’ S  N E W ? 
Data from the heart failure registries of the European Society of Cardiology showed that major electrocardiogram (ECG) 
abnormalities (simple ECG parameters: abnormal rhythm; >100 bpm; QRS ≥120 ms; QTc ≥450 ms; pathological Q-wave; left 
ventricular hypertrophy; left bundle branch block) were present in the majority of real-life heart failure patients. What is more, 
these major ECG abnormalities were more common in patients with reduced left ventricular ejection fraction. Assessment of 
these simple major ECG abnormalities showed association with a worse general condition and one-year outcomes. Among 
others, tachycardia was the strongest predictor of all-cause death. Results of the ECG examination should not be overlooked 
as may provide important information in risk stratification. 
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RESULTS
Prevalence of ECG abnormalities
There were 1222 out of 1460 (83.7%) HF patients with major 
ECG abnormalities. The most frequent ECG abnormalities in 
the entire cohort were: prolonged QTc interval (44.4%) and 
abnormal heart rhythm (36.0%). Differences in the presence 
of major ECG abnormalities were observed across the HF 
types, with the most prevalent changes observed in HFrEF 
patients (Table 1).
Clinical characteristics
Patients with abnormal ECG were older (median, 67.2 vs 
66 years; P = 0.03) and more often were male (68.1% 
vs 58.8%; P = 0.007) when compared with those with 
normal ECG. They were also more likely to have lower 
left ventricular ejection fraction (median, 35% vs 45%; 
P <0.001), moderate or severe valvular heart disease, 
ischemic heart disease, a history of atrial fibrillation, and 
chronic kidney disease than the patients with normal ECG. 
The group with abnormal ECG findings also had a higher 
NYHA class, higher concentrations of natriuretic peptides 
and more frequently required treatment with diuretics, 
antiarrhythmic (amiodarone and digitalis) and antico-
agulation than the patients with normal ECG. Detailed 
baseline clinical characteristics of both study groups are 
presented in Table 2.
Predictors of one-year outcomes
In a one-year follow-up the patients with abnormal ECG 
were more likely to reach the primary and secondary 
endpoints than those with normal ECG (13.8% vs 8.4%; 
P = 0.021 and 33% vs 24.7%; P = 0.016; respectively) (Table 
2). The Kaplan-Meier curves for the primary and secondary 
endpoints for both subgroups are shown in Figure 1A, B, 
respectively. 
Across the types of HF, HFrEF patients with abnormal 
ECG had worse one-year outcomes when compared with 
the HFmrEF and HFpEF groups (Table 3, Figure 1C, D).
In the total cohort, the presence of any ECG abnormality 
was a predictor of both the primary and secondary end-
points but only in the univariable analyses (Supplementary 
material, Table S1). The univariable analyses of specific ECG 
abnormalities revealed abnormal rhythm, tachycardia, 
QRS complex duration ≥120 ms, and QTc interval ≥450 ms 
(but not LBBB, pathological Q-wave, and left ventricular 
hypertrophy) to be predictors of both the primary and 
secondary endpoints (Supplementary material, Table S1). 
In the multivariable analysis, only tachycardia on ECG re-
mained an independent predictor of the primary endpoint 
(hazard ratio 1.75; 95% CI, 1.06–2.87; P = 0.03) but not of the 
secondary endpoint (hazard ratio 1.33; 95% CI, 0.93–1.90; 
P = 0.09) (Table 4). 
DISCUSSION
The results of this analysis provided important epidemio-
logical data on the prevalence, associated patients’ clinical 
characteristics, and relevance of basic ECG abnormalities in 
real-life HF patients. The study showed that ECG abnormal-
ities were present in the majority of HF patients but were 
observed more frequently in HFrEF patients. What is more, 
these easily measured ECG parameters reflected patients 
in worse general condition, with multiple comorbidities, 
and were associated with poor one-year outcomes. 
A standard 12-lead ECG is an essential diagnostic tool 
in clinical cardiology and crucial for the management of 
Table 1. Prevalence of major ECG abnormalities according to types of heart failure
Variable % of the total cohort; 
number of patients
HFrEF (n = 806) HFmrEF (n = 279) HFpEF (n = 375) P-value
Abnormal ECG 83.7%; 1222 88.7%; 715 83.9%; 234 72.8%; 273 0.14a
0.003b
<0.001c
Not sinus rhythm on ECG 36%; 526 34.9%; 281 34.1%; 95 40%; 150 0.18d
Tachycardia 5.8%; 85 6%; 48 6.1%; 17 5.3%; 20 0.91d
Pathological Q-wave 28.5%; 416 33%; 266 33%; 92 15.5%; 58 1.00a
<0.001b
<0.001c
LVH 19.5%; 285 19.7%; 159 24.7%; 69 15.2%; 57 0.27a
0.009b
0.21c
LBBB 12.3%; 180 16.7%; 135 10.4%; 29 4.3%; 16 0.042a
0.01b
<0.001c
QRS complex ≥120 ms 28.1%; 410 37.3%; 301 20.1%; 56 14.1%; 53 <0.001a
0.17b
<0.001c
QTc interval ≥450 ms 44.4%; 648 50.5%; 407 35.1%; 98 38.1%; 143 <0.001a
1.00b
<0.001c
aP-value for HFrEF vs HFmrEF after Bonferroni correction; bP-value for HFmrEF vs HFpEF after Bonferroni correction; cP-value for HFrEF vs HFpEF after Bonferroni correction; 
dP-value for overall test
Abbreviations: ECG, electrocardiogram; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with 
reduced ejection fraction; LBBB, left bundle branch block; LVH, left ventricular hypertrophy
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Table 2. Baseline characteristics and one-year outcomes of patients with abnormal or normal ECG
Variable Abnormal ECG (n = 1222) Normal ECG (n = 238) P-value
Baseline characteristics
Age, years 67.2 (58.2–77.0) 66.0 (54.8–76.6) 0.04
Male 68.1%; 832 58.8%; 140 0.01
BMI, kg/m2 27.8 (25.0–31.2); [1169] 27.8 (24.5–31.8); [227] 0.81
LVEF, % 35 (25–46) 45 (30–55.8) <0.001
HFrEF 58.5%; 715 38.2%; 91 <0.001
HFmrEF 19.1%; 234 18.9%; 45 0.80
HFpEF 22.3%; 273 42.8%; 102 <0.001
Previous HF hospitalization 75.4%; 921 68.1%; 162 0.03
Coronary artery disease 56%; 684 42.4%; 101 <0.001
Prior PCI or CABG 34.2%; 417 26.1%; 62 0.01
Moderate or severe mitral regurgitation 49.7%; 572/[1150] 30.7%; 67/[218] <0.001
Moderate or severe aortic stenosis 10.2%; 90/[882] 4.0%; 6/[151] 0.01
Hypertension 63.9%; 780 63.0%; 150 0.75
History of atrial fibrillation 46.5%; 568 21.1%; 50 <0.001
Peripheral artery disease 11.9%; 145 8.8%; 21 0.24
Diabetes 33.6%; 411 27.7%; 66 0.20
Chronic kidney disease 19.1%; 233 13.4%; 32 0.07
COPD 18.3%; 223 15.5%; 37 0.44
Prior stroke or TIA 12.0%; 146 10.1%; 24 0.73
CHA2DS2-VASc score 4 (3–5) 4 (2–5) 0.11
Current malignant disease 3.7%; 45 3.4%; 8 0.85
Current or former smoking 57.9%; 700 56.8%; 133 0.71
Alcohol usage 56.8%; 674 58.7 %; 135 0.59
Pacemaker 7.1%; 87 3.8%; 9 0.07
ICD 17.4%; 213 12.2%; 29 0.13
CRT 5.9%; 72 0.4%; 1 <0.001
Clinical status
Heart rate, bpm 80 (70–96) 76 (68–88.2) 0.01
SBP, mm Hg 130 (110–140) 130 (120–150) 0.003
DBP, mm Hg 80 (70–83) 80 (70–90) 0.03
NYHA class 3 (2–3); [1218] 2 (2–3); [237] <0.001
Anemia 32.4%; 298/[921] 34.6%; 56/[162] 0.29
Pleural effusion/congestion (X-ray) 39.2%; 360/[918] 27.0%; 47/[174] 0.003
Hemoglobin, g/dl 13.4 (11.9–14.4); [1140] 13.2 (11.1–14.4); [220] 0.31
Serum creatinine, mg/dl 1.1 (0.9–1.4); [1158] 1.0 (0.8–1.3); [214] 0.001
Serum sodium, mmol/l 139 (136–141); [1157] 139 (136–141); [220] 0.92
Serum potassium, mmol/l 4.4 (4.1–4.8); [1158] 4.4 (4.1–4.7); [220] 0.46
BNP, pg/ml 576 (203–1386.8); [163] 364 (155–643.5); [24] 0.01
NT-proBNP, pg/ml 3048 (1352–7024); [315] 1580 (419.5–4959.5); [55] 0.01
Pharmacotherapy
ACE-I 75.4%; 921/[1221] 75.6%; 180 0.93
ARB 10.2%; 124/[1219] 15.1%; 36 0.02
β-blocker 89.1%; 1088/[1221] 86.6%; 206 0.42
Diuretic 83.3%; 1016/[1220] 77.3%; 184 0.08
MRA 67.3%; 821/[1221] 58.6%; 139 0.01
Statins 65.9%; 805/[1221] 60.5%; 144 0.21
Oral Anticoagulant 45.4%; 554/[1221] 26.2%; 62 <0.001
Antiplatelets 60.0%; 732/[1221] 65.5%; 156 0.11
Digitalis 25.1%; 306[1221] 16.0%; 38 <0.001
Amiodarone 9.7%; 118/[1221] 5.9%; 14 0.16
Other Antiarrhythmic 6.1%; 75/[1221] 3.4%; 8 0.09
One-year outcomes
NYHA class I or II 68.2% 690/[1011] 81.0% 171/[211] <0.001
NYHA class III or IV 31.8% 321/[1011] 19% 40/[211]
Death 13.8%; 169 8.4%; 20 0.02
Death or rehospitalization 33%; 367/[1111] 24.7%; 53/[215] 0.02
Continuous variables are presented as medians and interquartile ranges (IQR);
Available cases count in the respective variable are presented in square brackets. 
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain natriuretic peptide; bpm, beats per minute; 
CABG, coronary artery bypass grafting; CHA2DS2VASc score, congestive heart failure, hypertension, age >75 years, diabetes mellitus, history of stroke or thromboembolism, vascular 
disease, age 65 to 74 years, female sex; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DBP, diastolic blood pressure; HF, heart failure; ICD, 
implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-brain natriuretic peptide;
NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TIA, transient ischemic attack. Other — see Table 1
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Table 3. One-year outcomes of patients with abnormal or normal electrocardiogram regarding to the type pf heart failure
Type of HF Abnormal ECG Normal ECG P-value
NYHA class
HFrEF 3 (2–4); n = 719 2 (2–3); n = 91 <0.001
HFmrEF 3 (2–3); n = 234 3 (2–3); n = 45 <0.001
HFpEF 3 (2–3); n = 273 3 (2–3); n = 102 0.20
Death
HFrEF 15.6%; 112/715 6.5%; 6/91 0.01
HFmrEF 8.1%; 19/234 6.6%; 3/45 1.00
HFpEF 13.9%; 38/273 10.7%; 11/102 0.49
Death or rehospitalization
HFrEF 36.9%; 239/648 29.6%; 24/81 0.22
HFmrEF 24.8%; 51/206 26.8%; 11/41 0.84
HFpEF 30%; 77/257 19.4%; 18/93 0.06
Abbreviations: see Table 1 and 2
patients with most cardiovascular conditions, including 
patients with HF. The advantages of ECG are simplicity 
of implementation, non-invasive nature, low cost, and 
wide availability. ECG is routinely performed in most HF 
patients, but frequently not enough attention is paid 
to its results. A normal ECG is infrequently observed in 
patients with suspected HF but it has a low specificity [9]. 
Analysis of EuroHeart Failure survey data showed that ECG 
Figure 1. A. Kaplan-Meier curves for the primary endpoint of patients with abnormal or normal ECG. B. Kaplan-Meier curves for the secondary 
endpoint of patients with abnormal or normal ECG. C. Kaplan-Meier curves for the primary endpoint of patients with abnormal ECG regarding to 
the type of heart failure. D. Kaplan-Meier curves for the secondary endpoint of patients with abnormal ECG regarding to the type of heart failure
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abnormalities (including ventricular rate, PR, QRS and QTc 
intervals, left ventriclar hypertrophy, pathological Q-wave, 
ST‐T‐wave abnormalities, and interventricular conduction 
abnormalities) were observed in more than 98% of HF 
patients [9]. In our study, we focused on the predefined 
major ECG parameters, which can be assumed as being in 
line with the previous observations.
All of the ECG abnormalities (except abnormal heart 
rhythm and tachycardia) were more prevalent in HFrEF 
patients when compared with patients with HFmrEF and 
HFpEF. Although it is known that heart rhythm abnormal-
ities (especially atrial fibrillation) are frequently present in 
patients with HFpEF [1, 10], the presence of ECG abnor-
malities was more commonly associated with a history 
of advanced heart valve disease, atrial fibrillation, chronic 
kidney disease, signs of HF decompensation (higher natriu-
retic peptides, pleural effusion, higher NYHA class) and use 
of diuretics and anticoagulants. 
A standard resting 12-lead ECG may reveal signs of 
inherited disorders but also suggests underlying structural 
heart disease, electrolyte disturbances and may reflect 
patients at higher risk of poor prognosis. In our study, the 
presence of at least one of the major ECG abnormalities and 
associated worse general condition at baseline translated 
into a worse prognosis in a one-year observation (higher 
rate of all-cause death, death, or HF hospitalization and 
higher NYHA class than in the patients without such ECG 
abnormalities). Among all tested major ECG abnormalities 
only tachycardia (defined as >100 bpm) was an inde-
pendent predictor of the primary endpoint but not the 
secondary endpoint. Important to note is that patients in 
the abnormal ECG group had significantly higher resting 
heart rates, despite the more frequent use of antiarrhythmic 
drugs (amiodarone, digitalis) and a high rate of β-blocker 
(89.2%) administration. A higher resting heart rate in HF 
patients was proven to be associated with higher long-term 
mortality [11, 12], particularly when above 110 bpm and 
with concomitant atrial fibrillation [13, 14]. 
It can be concluded that none of the other typical ECG 
parameters except tachycardia independently influenced 
the prognosis of patients with HF, regardless of the type of 
HF. However, it should also be emphasized that the presence 
of ECG abnormalities was a marker of patients in a worse 
clinical condition and with a worse one-year prognosis. 
In our study, QTc prolongation was the most frequent 
abnormality (44.4% and 50.5% of the whole cohort and 
HFrEF patients, respectively) but it was not an independent 
predictor of worse outcomes. Similarly, it was previously 
presented that QTc interval was frequently prolonged in 
HF patients (70% of patients had QTc ≥440 ms) but it was 
not associated with increased long-term mortality [15].
There is evidence that both patients with reduced or 
mildly reduced left ventricular ejection fraction (35%–50%) 
and with LBBB are at higher risk of death and HF hospital-
Table 4. Multivariable analysis of predictors of the primary and secondary endpoints in heart failure patients at one-year
Variable Primary endpoint (n = 189) Secondary endpoint (n = 420)
HR 95% CI P-value HR 95% CI P-value
Age 1.03 1.02–1.05 <0.001 1.01 0.99–1.02 0.20
Male – – – 0.77 0.62–0.96 0.03
BMI 0.98 0.95-1.01 0.21 – – –
NYHA (class III or IV vs I or II) 1.91 1.50–2.43 <0.001 2.02 1.52–2.68 <0.001
CKD 1.66 1.19–2.34 0.003 1.40 1.11–1.76 0.005
COPD 1.25 0.88–1.78 0.22 1.20 0.95–1.52 0.11
Diabetes 1.37 0.98–1.93 0.07 1.26 1.03–1.55 0.04
AF history 0.88 0.59–1.31 0.53 – – –
HGB 0.97 0.89–1.05 0.46 0.96 0.91–1.01 0.09
Serum sodium 0.92 0.90–0.94 <0.001 0.96 0.94–0.98 <0.001
SBP 1.00 0.99–1.01 0.92 0.996 0.99–1.0001 0.05
B-blocker 0.47 0.31–0.70 0.001 0.70 0.52–0.93 0.01
ARB 0.52 0.26–1.02 0.06 – – –
ACE-I 0.72 0.49–1.06 0.1 0.76 0.61–0.95 0.02
Abnormal rhythm 1.08 0.72–1.63 0.70 0.98 0.80–1.22 0.88
Tachycardia (>100 bpm) 1.84 1.12–3.03 0.02 1.41 0.98–2.01 0.06
QRS ≥120 ms 1.34 0.94–1.91 0.11 1.21 0.97–1.51 0.10
QTc interval ≥450 ms 1.13 0.81–1.59 0.46 1.14 0.92–1.41 0.22
Digitalis – – – 1.03 0.82–1.30 0.80
Amiodarone 1.66 1.06–2.62 0.03 1.19 0.87–1.62 0.29
Statins 0.76 0.54–1.08 0.12 – – –
HF type
HFmrEF (reference) 1.00 1.00–1.00 1.00 1.00 1.00–1.00 1.00
HFrEF 2.04 1.21–3.44 0.01 1.27 0.95–1.71 0.10
HFpEF 1.42 0.82–2.46 0.22 0.86 0.61–1.20 0.36
Abbreviations: ACE-I, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; bpm, beats per minute; CI, confi-
dence interval; CKD, chronic kidney disease; HGB, hemoglobin; HR, hazard ratio; SBP, systolic blood pressure. Other — see Table 1 and 2
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izations [16–18], and in selected cases, CRT might be par-
ticularly beneficial [1]. Similarly, QRS complex prolongation 
due to right ventricular pacing was shown to be associated 
with an increase in HF hospitalization [19]. In our study, 
LBBB was observed in 12.3% of the total cohort but it was 
not a predictor of a worse prognosis. It is worth noting that 
CRT was implanted in 5.8% of patients with the ECG abnor-
malities and nobody in the normal ECG group. It should 
also be highlighted that there are no standardized LBBB 
criteria, hence the clinical trials and registries used various 
and divergent definitions of LBBB. As a consequence, this 
translates into different observed rates of LBBB occurrence 
and associated prognosis [20].
Despite years of investigations, knowledge on the risk 
stratification for sudden cardiac death (SCD) in patients 
with HF is incomplete. The primary prevention of SCD 
is based only on left ventricular ejection fraction, which 
translates into difficulty in choosing patients who will 
benefit from ICD implantation, particularly among patients 
with nonischemic HF. Several ECG parameters alone or in 
combination were shown to have prognostic relevance 
(e.g. LBBB, prolonged QRS complex, prolonged QTc in-
terval) [6, 21]. However, despite certain clinical scenarios 
(CRT implantation, ICD implantation in secondary SCD 
prevention) they are used infrequently in risk stratification, 
particularly in patients with chronic HF, or at high risk of HF 
decompensation. Therefore, further research on better risk 
stratification in HF, including the risk of HF decompensation 
and mortality in different HF subgroups, is particularly 
warranted and is currently ongoing [22–24]. This might 
be an  important strategy in guiding the HF therapy to 
reduce risk via further intensification of pharmacological 
treatment or closer monitoring [25]. 
Limitations
The inclusion of real-life patients followed by cardiologists 
is an important advantage of ESCHF Pilot and ESCHFLT 
registries, but drawbacks include the partial incomplete-
ness of the data and the observational design. What is 
more, only the predefined ECG data in the Case Report 
Forms designed by the coordinators of the registries were 
available for analysis. The registries were not primarily fo-
cused on the ECG analysis, hence measurement errors are 
possible. There were no predefined definitions of the ECG 
parameters, including LBBB, pathological Q-wave, and left 
ventricular hypertrophy.
CONCLUSIONS
Results from a large real-world HF database of patients 
followed by cardiologists showed that ECG abnormalities 
were present in the majority of HF patients but more 
frequently in HFrEF patients. The patients with ECG abnor-
malities were characterized by a worse general condition 
and poor one-year outcomes when compared with thos 
without any abnormal ECG findings. Among other ECG 
abnormalities, only tachycardia was an independent pre-
dictor of all-cause mortality. 
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